Literature DB >> 18665782

A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase.

Wendy A Lea1, Ajit Jadhav, Ganesha Rai, Ahmed A Sayed, Cynthia L Cass, James Inglese, David L Williams, Christopher P Austin, Anton Simeonov.   

Abstract

Abstract: Schistosomiasis is a major neglected tropical disease that currently affects over 200 million people and leads to over 200,000 annual deaths. Schistosoma mansoni parasites survive in humans in part because of a set of antioxidant enzymes that continuously degrade reactive oxygen species produced by the host. A principal component of this defense system has been recently identified as thioredoxin glutathione reductase (TGR), a parasite-specific enzyme that combines the functions of two human counterparts, glutathione reductase and thioredoxin reductase, and as such this enzyme presents an attractive new target for anti-schistosomiasis drug development. Herein, we present the development of a highly miniaturized and robust screening assay for TGR. The 5-mul final volume assay is based on the Ellman reagent [5,5'-dithiobis(2-nitrobenzoic acid) (DTNB)] and utilizes a high-speed absorbance kinetic read to minimize the effect of dust, absorbance interference, and meniscus variation. This assay is further applicable to the testing of other redox enzymes that utilize DTNB as a model substrate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665782      PMCID: PMC2669305          DOI: 10.1089/adt.2008.149

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  23 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  A high-throughput screen for aggregation-based inhibition in a large compound library.

Authors:  Brian Y Feng; Anton Simeonov; Ajit Jadhav; Kerim Babaoglu; James Inglese; Brian K Shoichet; Christopher P Austin
Journal:  J Med Chem       Date:  2007-04-21       Impact factor: 7.446

3.  Recommendations for the reduction of compound artifacts in time-resolved fluorescence resonance energy transfer assays.

Authors:  Pierre-Eloi Imbert; Vincent Unterreiner; Daniela Siebert; Hanspeter Gubler; Christian Parker; Daniela Gabriel
Journal:  Assay Drug Dev Technol       Date:  2007-06       Impact factor: 1.738

Review 4.  Antischistosomal drugs: past, present ... and future?

Authors:  D Cioli; L Pica-Mattoccia; S Archer
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

5.  Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni.

Authors:  Ahmed A Sayed; David L Williams
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

6.  Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.

Authors:  Anton Simeonov; Adam Yasgar; Ajit Jadhav; G L Lokesh; Carleen Klumpp; Sam Michael; Christopher P Austin; Amarnath Natarajan; James Inglese
Journal:  Anal Biochem       Date:  2007-12-05       Impact factor: 3.365

Review 7.  Praziquantel.

Authors:  Donato Cioli; Livia Pica-Mattoccia
Journal:  Parasitol Res       Date:  2002-11-22       Impact factor: 2.289

8.  Cytotoxicity of furoxans: quantitative structure-activity relationships study.

Authors:  Mariana Boiani; Hugo Cerecetto; Mercedes González
Journal:  Farmaco       Date:  2004-05

9.  Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni.

Authors:  P G Fallon; R F Sturrock; A C Niang; M J Doenhoff
Journal:  Am J Trop Med Hyg       Date:  1995-07       Impact factor: 2.345

10.  Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade.

Authors:  Anton Simeonov; Ajit Jadhav; Ahmed A Sayed; Yuhong Wang; Michael E Nelson; Craig J Thomas; James Inglese; David L Williams; Christopher P Austin
Journal:  PLoS Negl Trop Dis       Date:  2008-01-02
View more
  13 in total

1.  Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni.

Authors:  Hsin-Hung Huang; Latasha Day; Cynthia L Cass; David P Ballou; Charles H Williams; David L Williams
Journal:  Biochemistry       Date:  2011-06-10       Impact factor: 3.162

Review 2.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target.

Authors:  R S Treger; A G Cook; G Rai; D J Maloney; A Simeonov; A Jadhav; C J Thomas; D L Williams; M Cappello; J J Vermeire
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-05-18       Impact factor: 4.077

4.  Thioredoxin and glutathione systems differ in parasitic and free-living platyhelminths.

Authors:  Lucía Otero; Mariana Bonilla; Anna V Protasio; Cecilia Fernández; Vadim N Gladyshev; Gustavo Salinas
Journal:  BMC Genomics       Date:  2010-04-13       Impact factor: 3.969

5.  Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.

Authors:  Ganesha Rai; Ahmed A Sayed; Wendy A Lea; Hans F Luecke; Harinath Chakrapani; Stefanie Prast-Nielsen; Ajit Jadhav; William Leister; Min Shen; James Inglese; Christopher P Austin; Larry Keefer; Elias S J Arnér; Anton Simeonov; David J Maloney; David L Williams; Craig J Thomas
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

6.  Effects of Mammalian Thioredoxin Reductase Inhibitors.

Authors:  Elias S J Arnér
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  The pilot phase of the NIH Chemical Genomics Center.

Authors:  Craig J Thomas; Douglas S Auld; Ruili Huang; Wenwei Huang; Ajit Jadhav; Ronald L Johnson; William Leister; David J Maloney; Juan J Marugan; Sam Michael; Anton Simeonov; Noel Southall; Menghang Xia; Wei Zheng; James Inglese; Christopher P Austin
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 8.  Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.

Authors:  José T Moreira-Filho; Arthur C Silva; Rafael F Dantas; Barbara F Gomes; Lauro R Souza Neto; Jose Brandao-Neto; Raymond J Owens; Nicholas Furnham; Bruno J Neves; Floriano P Silva-Junior; Carolina H Andrade
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

9.  Gene gun bombardment with DNA-coated golden particles enhanced the protective effect of a DNA vaccine based on thioredoxin glutathione reductase of Schistosoma japonicum.

Authors:  Yan Cao; Bin Zhao; Yanhui Han; Juan Zhang; Xuezhen Li; Chunhui Qiu; Xiujuan Wu; Yang Hong; Dezhou Ai; Jiaojiao Lin; Zhiqiang Fu
Journal:  Biomed Res Int       Date:  2012-12-31       Impact factor: 3.411

10.  High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis.

Authors:  Ting Li; Peter D Ziniel; Pan-Qing He; Valerie P Kommer; Gregory J Crowther; Min He; Qing Liu; Wesley C Van Voorhis; David L Williams; Ming-Wei Wang
Journal:  Infect Dis Poverty       Date:  2015-08-31       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.